Hyperalgesia is an amplified pain response to noxious stimuli, where tissues that should hurt a little hurt a lot. It arises from dual mechanisms: peripheral sensitization (lowered nociceptor thresholds via inflammatory mediators) and central sensitization (spinal cord and supraspinal amplification of pain signals through NMDA receptor-mediated long-term potentiation and disinhibition of descending pain pathways). Hyperalgesia represents maladaptive neuroplasticity—the nervous system learning pain too well.
The Overly Sensitive Car Alarm
Imagine a car alarm calibrated to detect real threats—someone smashing a window. That's normal nociception. Now imagine that alarm gets recalibrated: first at the sensor level (peripheral sensitization), where the vibration detector becomes so sensitive that a falling leaf triggers it. Then at the control unit level (central sensitization), where the alarm's internal circuit board amplifies every signal tenfold and disables the "ignore minor vibrations" setting. Soon, a gentle breeze sets off the siren.
This is hyperalgesia. The peripheral sensors (nociceptors) have been bathed in inflammatory soup—TNF-α, PGE2, NGF—lowering their firing threshold like turning the sensor dial from "8" to "2." Meanwhile, the spinal cord's dorsal horn (the control unit) has undergone long-term potentiation at NMDA receptors, creating a hair-trigger amplification circuit. Touch-sensitive Aβ-fibres that normally report "gentle pressure" start sprouting into pain-processing zones (lamina II), like adding motion detectors to the alarm system where only break-in sensors should be. The brain's "ignore false alarms" descending inhibition from the periaqueductal gray weakens, like disabling the alarm's shut-off button. The result: a system that screams at whispers.
Hyperalgesia develops through parallel peripheral and central mechanisms that synergize to create profound pain amplification:
graph TD
A[Tissue injury/inflammation] --> B[Release of inflammatory mediators]
B --> C[PGE2]
B --> D["TNF-α"]
B --> E[NGF]
B --> F[Bradykinin]
C --> G[EP receptor activation on nociceptor]
D --> H[TNFR1 activation on nociceptor]
E --> I[TrkA receptor activation]
F --> J[B2 receptor activation]
G --> K[PKA activation]
H --> K
I --> K
J --> K
K --> L[Phosphorylation of TRPV1, ASIC, Nav1.7-1.9]
L --> M[Lower threshold for action potentials]
M --> N[Peripheral hyperalgesia]
Peripheral Level:
- Inflammatory mediator release → PGE2 (from COX-2), TNF-α, NGF, bradykinin, histamine accumulate at injury site
- PGE2 → EP receptor (Gαs-coupled) → ↑ cAMP → PKA activation → phosphorylation of TRPV1 channels and voltage-gated sodium channels (Nav1.7, Nav1.8, Nav1.9)
- TNF-α → TNFR1 → NF-κB activation → upregulation of Nav1.7 expression + direct phosphorylation of ion channels
- NGF → TrkA receptor → MAPK/ERK and PI3K/Akt pathways → increased TRPV1 insertion into membrane + sensitization of TRPV1 to lower temperatures (now activates at 37°C instead of 43°C)
- Bradykinin → B2 receptor → PLC → IP3/DAG → PKC activation → phosphorylation of TRPV1 and Nav channels
- Result: Nociceptor activation threshold drops from ~43°C (heat) or ~500 kPa (pressure) to 37°C or 100 kPa
graph TD
A[Sustained C-fibre input] --> B["Glutamate + Substance P release in dorsal horn"]
B --> C[NMDA receptor activation]
C --> D["Ca²⁺ influx"]
D --> E[CaMKII activation]
E --> F[Phosphorylation of AMPA receptors]
F --> G[Increased AMPA conductance]
D --> H[PKC activation]
H --> I["NMDA receptor Mg²⁺ block removal"]
I --> J[Positive feedback loop]
D --> K[CREB activation]
K --> L["c-Fos/c-Jun → AP-1"]
L --> M[Transcription of COX-2, iNOS, cytokines]
M --> N[Microglial activation]
N --> O["TNF-α/IL-1β release in spinal cord"]
O --> P[Further NMDA potentiation]
G --> Q[Long-term potentiation]
J --> Q
P --> Q
Q --> R[Central hyperalgesia]
R --> S["Aβ-fibre sprouting into lamina II"]
S --> T["Allodynia + secondary hyperalgesia"]
Central Level (Spinal Dorsal Horn):
- Phase 1 (Induction): Sustained C-fibre nociceptive input → massive glutamate + Substance P release in lamina I-II
- NMDA receptor activation: Glutamate binds → voltage-dependent Mg²⁺ block removed by prior AMPA depolarization → Ca²⁺ influx
- Immediate consequences:
- Ca²⁺ → CaMKII phosphorylates AMPA receptors → increased conductance (5-10x baseline)
- Ca²⁺ → PKC removes residual Mg²⁺ block from NMDA receptors → positive feedback
- Ca²⁺ → nitric oxide synthase (NOS) → NO diffuses to presynaptic terminal → enhanced glutamate release
- Phase 2 (Maintenance): Ca²⁺ → CREB phosphorylation → c-Fos/c-Jun (immediate early genes) → COX-2, iNOS, BDNF transcription
- Glial involvement:
- Activated microglia release TNF-α, IL-1β, IL-6 in spinal cord
- TNF-α → TNFR1 on neurons → lowers action potential threshold by 10-15 mV (from -55 mV to -40 mV)
- IL-1β → IL-1R → further NMDA potentiation + reduced GABA/glycine inhibitory tone
- Structural plasticity:
- BDNF → TrkB receptor → sprouting of Aβ-fibres (normally terminate in lamina III-IV) into lamina II (pain-processing zone)
- Normally, only C-fibres and Aδ-fibres synapse in lamina II; now touch fibres do too → allodynia (touch = pain)
- Dendritic spine density in dorsal horn neurons increases 40-60% within 24-48 hours
Descending Modulation Failure:
- Normal: periaqueductal gray (PAG) → rostral ventromedial medulla (RVM) → serotonergic/noradrenergic descending inhibition blocks nociceptive transmission
- In hyperalgesia: chronic pain → ↓ opioid receptor expression in PAG → ↓ descending inhibition + ↑ descending facilitation from RVM "ON cells"
- Net effect: spinal cord hyperexcitability is unopposed
TNF-α as Master Regulator:
- Both peripheral and central TNF-α create bidirectional sensitization
- Peripheral TNF-α → sensitizes nociceptors
- Central TNF-α (from activated microglia) → dramatically lowers neuronal firing threshold in dorsal horn + reduces inhibitory GABAergic tone by 30-40%
- TNF-α in CSF >10 pg/mL correlates with clinical hyperalgesia in fibromyalgia
Hyperalgesia is the hallmark of central sensitization syndromes—conditions where the nervous system's gain control is pathologically amplified. This is evolutionarily a mismatch: acute hyperalgesia around an injury (inflammatory hyperalgesia) protects healing tissue, but chronic hyperalgesia becomes the disease itself.
- Fibromyalgia: Diffuse, bilateral hyperalgesia with pain threshold <4 kg/cm² on pressure algometry (normal >6 kg/cm²)
- Complex Regional Pain Syndrome (CRPS): Severe hyperalgesia extending beyond injury zone (secondary hyperalgesia)
- Small fiber neuropathy: Loss of protective C-fibres paradoxically creates hyperalgesia via Aδ-fibre dominance and central sensitization
- Post-surgical chronic pain: 10-50% of surgeries lead to persistent hyperalgesia via perioperative inflammation priming central sensitization
- Neuropathic pain syndromes: Diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy
- Chronic low back pain: Once hyperalgesia develops, tissue healing is no longer the issue—the nervous system is
- Selfish Nervous System: Once central sensitization establishes, the nervous system consumes massive glucose (PET shows 30-40% ↑ glucose uptake in dorsal horn and thalamus) and prioritizes its own threat-detection over metabolic economy
- Evolutionary Mismatch: Chronic low-grade inflammation from modern diet/lifestyle (↑ omega-6, ↓ omega-3, chronic stress → ↑ cortisol → glucocorticoid resistance) creates persistent peripheral sensitization that was never selected for
- Bonding System Failure: Chronic pain → ↓ oxytocin → ↓ endogenous opioid analgesia → hyperalgesia worsens (positive feedback loop)
What NOT to do:
- Peripheral-only interventions (NSAIDs, local anaesthetics) fail because central sensitization is maintained independently
- Opioids worsen hyperalgesia long-term via opioid-induced hyperalgesia (OIH) through NMDA activation
What TO do:
- Cold therapy (most effective for hyperalgesia): 10-15°C water immersion 3-5 min → activates TRPM8 channels → releases endogenous opioids + adenosine → inhibits NMDA activation. Clinical threshold: reduces mechanical hyperalgesia by 40-60% within 2 weeks (evidence from Pruimboom protocols)
- Pain neuroscience education: Explaining the biology reduces threat perception → ↓ anterior cingulate cortex hyperactivity → ↓ descending facilitation
- Graded motor imagery: Retrains cortical body maps without triggering pain → reverses maladaptive plasticity in S1/M1
- NMDA antagonists (ketamine, magnesium): Block central sensitization maintenance. Ketamine 0.1-0.5 mg/kg IV resets hyperalgesia for weeks in 60% of patients
- Specialized pro-resolving mediators (SPMs): Resolvins, protectins, maresins inhibit TNF-α and shift from inflammatory lipid mediators (LTB4, PGE2) to resolution → reverses peripheral + central sensitization
- Exercise paradox: Initially worsens hyperalgesia (mechanical load → inflammatory pulse), but chronic aerobic exercise (>8 weeks) → ↑ BDNF, ↑ endocannabinoids, ↑ descending inhibition → resets pain threshold upward
- Quantitative Sensory Testing (QST): Mechanical pain threshold <200 g (von Frey), heat pain threshold <43°C
- Temporal summation: Repeated stimuli at 0.5 Hz show escalating pain (wind-up) — tests NMDA-dependent central sensitization
- Conditioned Pain Modulation (CPM): Reduced pain inhibition by distant noxious stimulus (<10% reduction vs normal 30-40%) indicates failed descending modulation
- TNF-α in CSF: >10 pg/mL
- PET imaging: ↑ glucose metabolism in thalamus, ACC, insula, S1 during rest (not just during pain)
- Peripheral sensitization lowers nociceptor threshold from 43°C (heat) to 37°C—body temperature itself becomes painful
- TNF-α in the CNS lowers neuronal action potential threshold by 10-15 mV, making spontaneous firing commonplace
- NMDA receptor activation requires dual signals: glutamate binding + sufficient depolarization to remove Mg²⁺ block (requires ~20 mV depolarization)
- Central sensitization can persist for months after peripheral injury heals—the spinal cord "remembers" pain via LTP mechanisms
- Aβ-fibre sprouting into lamina II occurs within 24-72 hours of sustained C-fibre input—this creates allodynia (light touch = pain)
- Mechanical pain threshold in fibromyalgia averages 2.6 kg/cm² vs 6.8 kg/cm² in healthy controls (60% reduction)
- Cold therapy (10-15°C, 3-5 min) is the single most effective non-pharmacological intervention for hyperalgesia, reducing mechanical sensitivity 40-60% within 2 weeks
- Microglial activation in spinal dorsal horn persists for 3-6 months after peripheral injury resolves, maintaining central sensitization
- Hyperalgesia spreads beyond injury site (secondary hyperalgesia) due to central amplification—pain in the hand from an elbow injury signals central sensitization
- Sleep deprivation worsens hyperalgesia by 20-30% via ↓ adenosine tone and ↑ IL-6 (one night of poor sleep measurably lowers pain threshold)
- Opioid-induced hyperalgesia (OIH) occurs in 30-50% of chronic opioid users through NMDA-dependent mechanisms—the drug meant to treat pain creates more pain
- PET imaging shows 30-40% increased glucose uptake in dorsal horn, thalamus, and ACC in chronic hyperalgesia patients—a metabolically expensive state
- central sensitization — hyperalgesia is the clinical manifestation of central sensitization's neuroplastic changes in spinal and supraspinal pain pathways
- peripheral sensitization — inflammatory mediators (PGE2, TNF-α, NGF) lower nociceptor activation threshold, creating the first phase of hyperalgesia before central mechanisms amplify it
- allodynia — sister phenomenon where non-noxious stimuli cause pain; develops via Aβ-fibre sprouting into lamina II during hyperalgesia progression
- fibromyalgia — chronic widespread hyperalgesia is the defining feature; pressure pain threshold <4 kg/cm² vs normal >6 kg/cm²
- TNF-α — master cytokine driving both peripheral nociceptor sensitization and central neuronal hyperexcitability; CSF levels >10 pg/mL predict hyperalgesia severity
- NMDA receptor — glutamate-gated Ca²⁺ channel essential for central sensitization and long-term potentiation in dorsal horn; Mg²⁺ block removal is the gate to hyperalgesia
- neuropathic pain — paradoxically, nerve damage (loss of C-fibres) often causes hyperalgesia via compensatory central sensitization and Aδ-fibre dominance
- small fiber neuropathy — loss of protective C-fibres creates hyperalgesia through unmasking of Aδ-fibre input and central disinhibition
- inflammation — acute inflammatory mediators (PGE2, bradykinin, NGF) sensitize nociceptors; chronic low-grade inflammation maintains peripheral priming
- pain threshold — hyperalgesia represents a pathological downward shift; mechanical threshold drops 60% in fibromyalgia, heat threshold drops from 43°C to 37°C
- dorsal horn — site of central sensitization; NMDA-dependent LTP in lamina I-II neurons amplifies all incoming nociceptive signals 5-10x
- long-term potentiation — the same NMDA-dependent plasticity that enables learning in hippocampus creates pathological pain memory in spinal cord
- cold therapy — most effective intervention for hyperalgesia; activates TRPM8 channels, releases endogenous opioids and adenosine, inhibits NMDA signaling
- pain neuroscience education — cognitive intervention explaining pain biology reduces threat appraisal in ACC and vmPFC, decreasing descending facilitation and central gain
- neuroinflammation — microglial activation in spinal cord and brain releases TNF-α, IL-1β, IL-6 that potentiate NMDA receptors and reduce GABAergic inhibition
- NGF — nerve growth factor binds TrkA receptors on nociceptors, lowering TRPV1 activation temperature to 37°C and increasing Nav1.7 expression
- PGE2 — prostaglandin E2 from COX-2 activates EP receptors on nociceptors, triggering PKA-mediated phosphorylation of TRP channels and sodium channels
- lamina II — normally receives only C-fibre (pain) and Aδ-fibre input; in hyperalgesia, Aβ-fibres sprout here within 48 hours, creating allodynia
- descending pain modulation — periaqueductal gray → RVM pathway normally inhibits nociception; hyperalgesia involves failure of descending inhibition + activation of descending facilitation
- chronic pain — hyperalgesia is the transition point from acute protective pain to chronic maladaptive pain; once central sensitization consolidates (>3 months), tissue healing is irrelevant
- TRPV1 — capsaicin receptor on nociceptors; NGF and PGE2 sensitize it to activate at body temperature (37°C) instead of 43°C, creating heat hyperalgesia
- microglial activation — spinal microglia release TNF-α, IL-1β that directly potentiate NMDA receptors and reduce inhibitory GABAergic tone; persist 3-6 months post-injury
- BDNF — brain-derived neurotrophic factor released from dorsal horn neurons drives Aβ-fibre sprouting into lamina II via TrkB receptor activation
- opioid tolerance — chronic opioid exposure activates NMDA receptors, creating opioid-induced hyperalgesia (OIH) in 30-50% of users—pain treatment becomes pain cause
- specialized pro-resolving mediators (SPMs) — resolvins, protectins, maresins actively terminate inflammatory phase, inhibit TNF-α, and reverse peripheral + central sensitization
- periaqueductal gray — midbrain structure controlling descending pain modulation; chronic pain reduces opioid receptor expression here, losing top-down inhibition
- anterior cingulate cortex — processes pain unpleasantness; hyperactive in hyperalgesia due to threat amplification; targeted by pain neuroscience education to reduce descending facilitation
- IL-1β — interleukin-1β from activated spinal microglia potentiates NMDA receptors and suppresses GABAergic inhibition, maintaining central sensitization
- COX-2 — cyclooxygenase-2 upregulated in spinal cord during central sensitization via CREB/c-Fos; produces PGE2 that amplifies nociceptive signaling centrally
- chronic low-grade inflammation — evolutionary mismatch state (modern diet, stress, sleep deprivation) maintains peripheral nociceptor priming, predisposing to hyperalgesia with any injury